Centre Hospitalier Regional d'Orleans (CHRO) - Hopital La Source

Orléans 45067

0 studies enrolling now · 1 studies all time

What they study most

Bladder Cancer

Studies at this site

• A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) — Running, not enrolling